Abstract
Introduction: ADCC by natural killer (NK) cells is a key mechanism for several clinically successful tumor-targeting therapeutic antibodies. Most patients, however, have limited responses to this therapy and/or develop resistance. NK cells exclusively recognize IgG by their low-affinity FcγR CD16A. Areas covered: We describe in this editorial a novel recombinant FcγR that consists of CD64, the only high affinity IgG receptor, and the transmembrane and cytoplasmic regions of CD16A, a potent activating receptor. CD64/16A was expressed in engineered iPSCs that were differentiated into NK cells (referred to as iNK cells). Expert opinion: iNK-CD64/16A cells in combination with therapeutic antibodies provide a universal tumor antigen targeting approach and potential off-the-shelf cell therapy to treat various malignancies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1229-1232 |
| Number of pages | 4 |
| Journal | Expert opinion on biological therapy |
| Volume | 19 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2 2019 |
Bibliographical note
Funding Information:This paper was funded by the National Institutes of Health, including R01CA203348 and R21AI125729, and the Minnesota Ovarian Cancer Alliance.
Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
Keywords
- Fc receptor
- Natural killer cells
- antibody
- cancer
- cell therapy
- mAb therapy
- stem cell
